BioPharmSignal logoBioPharmSignal

Biotech News

Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules

Pulse Biosciences (PLSE)Pulse BiosciencesCompany update

Completed 100 patient enrollment across three U.S. sites; first patient enrolled completed 12-month follow-up HAYWARD, Calif. --(BUSINESS WIRE)--Sep. 15, 2026-- Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™

Related news

PLSEPulse Biosciences2026-10-07 11:00 EST

Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Treatment

PLSEPulse Biosciences2026-11-06 12:00 EST

Pulse Biosciences Presents Six-Month Interim Results from the PRECISE-BTN Multicenter Study at the American Thyroid Association Annual Meeting

HYPRHyperfine2026-09-15 12:15 EST

Hyperfine Announces Completion of Enrollment in the Contrast PMR Study to Support the Submission to Expand Indications for Use of the Swoop® System with Contrast Agents

DCTHDelcath Systems2026-10-19 20:01 EST

Delcath Systems Highlights Clinical Program Presentations at ESMO Congress 2026 and Independent Data on Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma

ICCMIceCure Medical2026-10-27 12:33 EST

IceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer Cryoablation

TMCITreace Medical Concepts2026-09-17 21:16 EST

Treace Announces Results of Three Clinical Studies Including the Milestone 5-Year ALIGN3D® Study Demonstrating Sustained, Positive Outcomes of the Lapiplasty® Procedure

TMCITreace Medical Concepts2026-09-15 21:07 EST

Treace Highlights Product Innovations and Clinical Data Across its Expanding Foot & Ankle Portfolio at the 2026 AOFAS Annual Meeting

IARTIntegra LifeSciences2026-10-16 12:40 EST

Integra LifeSciences to Highlight ENT and Instruments Portfolios and Sponsor New Clinical Research Presentations at AAO-HNSF 2026 Annual Meeting

IRIXIRIDEX2026-10-12 11:00 EST

Iridex Announces the Publication of Two-Year Independent Study Supporting Benefits of MicroPulse® Technology for Early to Advanced Glaucoma

SGHTSight Sciences2026-10-01 11:05 EST

Sight Sciences to Debut the OMNI Ultra® Surgical System, the Latest Technology Advancement from the Pioneers of Ab Interno Canaloplasty, at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting

View all latest news

Pulse Biosciences

Nanosecond Pulsed-Field Ablation Pulse Biosciences develops the nPulse platform, which delivers proprietary nanosecond pulsed-field energy to ablate targeted tissue. The technology is designed to create nonthermal cellular effects and is being evaluated in cardiac and soft-tissue applications. Cardiac Catheter System The nPulse Cardiac...

Recent company news

PLSEPulse Biosciences2026-11-06 12:00 EST

Pulse Biosciences Presents Six-Month Interim Results from the PRECISE-BTN Multicenter Study at the American Thyroid Association Annual Meeting

PLSEPulse Biosciences2026-11-05 21:05 EST

Pulse Biosciences Reports Business Updates and Third Quarter 2026 Financial Results

PLSEPulse Biosciences2026-10-29 17:05 EST

Pulse Biosciences to Present at Stifel 2026 Healthcare Conference

PLSEPulse Biosciences2026-10-22 20:05 EST

Pulse Biosciences Schedules Third Quarter 2026 Financial Results Conference Call for November 5, 2026

PLSEPulse Biosciences2026-10-14 11:00 EST

Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center

Stock data

Close
53.07 USD
Market cap
1.68B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States